SanegeneBio, a clinical-stage biotechnology company based in Masschusetts with significant presence in China, announced a global licensing agreement with Roche Group member Genentech, granting the latter exclusive worldwide rights to one of its proprietary RNAi programs. Under the agreements framework, SanegeneBio will receive a USD 200 million upfront payment and potential milestone payments totaling up to USD 1.5 billion, alongside tiered royalty structures.
SanegeneBio will be responsible for early-stage development activities with Genentech assuming subsequent clinical development and global commercialization responsibilities. The deal highlights the growing strategic importance of licensing agreements in biotechnology’s innovation ecosystem.
SanegeneBio’s proprietary RNAi platform incorporates novel chemistries and delivery technologies designed to generate potentially breakthrough small interfering RNA (siRNA) medicines. The platform’s key differentiator lies in its tissue-selective LEAD delivery technology, which enables precise genetic targeting across multiple disease areas.
Industry context
RNAi technologies represent a cutting-edge approach to genetic medicine, offering potential interventions in previously challenging therapeutic domains. By targeting gene expression at the molecular level, these platforms can potentially address complex genetic mechanisms underlying various diseases.
In recent years, Roche and its subsidiary Genentech have aggressively expanded their RNA footprint, shifting from a historical focus on small molecules and antibodies to a “multi-modality” strategy. This has been driven largely by the establishment of the Roche RNAHub, an integrated R&D unit designed to consolidate internal expertise and external partnerships. Other RNA-focused deals struck by Roche/Genentech include:
- Ascidian Therapeutics for RNA exon editing therapeutics in neurological conditions, for USD 42 million upfront and up to USD 1.8 billion in milestones (June 2024)
- Remix Therapeutics for small molecules that can reprogram how RNA is spliced or processed, with relevance across multiple disease areas, for USD 30 million upfront, USD 12 million near-term milestones, and total deal value exceeding USD 1 billion (January 2024)
- Alnylam for co-development and commercialization of zilebesiran (RNAi therapeutic for hypertension), for USD 310 million upfront, USD 2.8 billion total value (2023)